08:26 AM EST, 11/13/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Wednesday the full results of its phase 3 study on lenacapavir, an investigational HIV prevention injection, showed high rates of infection reductions.

The company said that 99.9% of lenacapavir participants did not acquire HIV, with only two cases among 2,179 participants that reported high levels of sexual behavior, chemsex and sexually transmitted infections.

Gilead said lenacapavir also showed superiority to its commercialized HIV treatment Truvada for pre-exposure prophylaxis, or preventing HIV in people at risk.

Price: 94.34, Change: -0.01, Percent Change: -0.01